Literature DB >> 24928080

Natural course of LGI1 encephalitis: 3-5 years of follow-up without immunotherapy.

Monika Szots1, Annamaria Marton1, Ferenc Kover2, Tunde Kiss3, Timea Berki4, Ferenc Nagy1, Zsolt Illes5.   

Abstract

Antibodies against LGI1 (leucin-rich glioma-inactivated 1 protein) are associated with limbic encephalitis (LE), which is characterized by a favorable outcome following immunotherapy. Here, we present two cases, where antibodies against LGI1 were detected in the sera 36 and 53 months after acute LE, respectively, and none of the patients received immunotherapy. LE showed characteristics of LGI1 encephalitis in both cases, including low sodium content in the sera; disorientation, hallucination, short-term memory loss; and epileptic seizures. One patient had faciobrachial tonic seizures. MRI indicated bilateral inflammation of the hippocampus in one case. We reviewed longitudinal clinical and MRI data covering 53 and 36 months after LE without immunotherapy, respectively. Both patients became seizure-free and spontaneously recovered with mild/moderate cognitive impairment. No relapses have been observed. Follow-up brain MRI indicated early hippocampal sclerosis and global brain atrophy in one case characterized by more pronounced cognitive deficit. Memory and verbal fluency were affected most during the natural course of LGI1 encephalitis. LGI1 encephalitis had a monophasic course and spontaneously improved, suggesting that a relatively benign natural course may contribute to the favorable outcome observed after immunotherapy. Our data also indicate that LGI1 antibodies can be present in the sera without clinical disease activity.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody-mediated encephalitis; Faciobrachial dystonic seizures; Hyponatremia; LGI1; Limbic encephalitis; Surface neuronal antibodies

Mesh:

Substances:

Year:  2014        PMID: 24928080     DOI: 10.1016/j.jns.2014.05.048

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

1.  Supratentorial white matter blurring associated with voltage-gated potassium channel-complex limbic encephalitis.

Authors:  H Urbach; S Rauer; I Mader; S Paus; J Wagner; M P Malter; H Prüss; J Lewerenz; J Kassubek; H Hegen; M Auer; F Deisenhammer; F Ufer; C G Bien; A Baumgartner
Journal:  Neuroradiology       Date:  2015-08-21       Impact factor: 2.804

2.  Rapidly progressive global cerebral atrophy in the setting of anti-LGI1 encephalitis.

Authors:  Anudeep Yelam; Elanagan Nagarajan; Pradeep C Bollu
Journal:  BMJ Case Rep       Date:  2019-05-24

3.  Posterior reversible encephalopathy syndrome as initial manifestation of autoimmune encephalitis.

Authors:  Jaeho Kim; Soon-Tae Lee; Silvia Park; Eun Yeon Joo; Chin-Sang Chung; Mi Ji Lee
Journal:  Neurol Clin Pract       Date:  2019-10

Review 4.  Seizures and Epilepsies due to Channelopathies and Neurotransmitter Receptor Dysfunction: A Parallel between Genetic and Immune Aspects.

Authors:  Agustina M Lascano; Christian M Korff; Fabienne Picard
Journal:  Mol Syndromol       Date:  2016-07-22

Review 5.  Shared Decision-making in Autoimmune Neurology: Making Decisions in the Face of Uncertainty.

Authors:  David A Lapides
Journal:  Neurol Clin Pract       Date:  2021-04

6.  A case of autoimmune epilepsy associated with anti-leucine-rich glioma inactivated subunit 1 antibodies manifesting electrical shock-like sensations and transparent sadness.

Authors:  Yoshiko Murata; Osamu Watanabe; Go Taniguchi; Daichi Sone; Mao Fujioka; Mitsutoshi Okazaki; Eiji Nakagawa; Yutaka Watanabe; Masako Watanabe
Journal:  Epilepsy Behav Case Rep       Date:  2015-09-26

Review 7.  Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions.

Authors:  James Varley; Angela Vincent; Sarosh R Irani
Journal:  J Neurol       Date:  2014-12-10       Impact factor: 4.849

8.  Clinical analysis of leucine-rich glioma inactivated-1 protein antibody associated with limbic encephalitis onset with seizures.

Authors:  Zhimei Li; Tao Cui; Weixiong Shi; Qun Wang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 9.  Antibody-associated epilepsies: Clinical features, evidence for immunotherapies and future research questions.

Authors:  Ochuko D Bakpa; Markus Reuber; Sarosh R Irani
Journal:  Seizure       Date:  2016-07-15       Impact factor: 3.184

Review 10.  Treatment strategies for autoimmune encephalitis.

Authors:  Yong-Won Shin; Soon-Tae Lee; Kyung-Il Park; Keun-Hwa Jung; Ki-Young Jung; Sang Kun Lee; Kon Chu
Journal:  Ther Adv Neurol Disord       Date:  2017-08-16       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.